pmol/L), GM-CSF (30 U/mL), a combination of AZT (1 pmol/L)/GM-CSF (30 U/mL), or medium control. At 10 or 20 days post-infection, phytohemagglutinin (PHAI-stimulated peripheral blood mononuclear leukocytes (PBMLs) were added t o the AM cultures as stimulated target cells. AZT effectively suppressed HIV replication and prevented transfer/amplification in target PBMLs as long as the drug was maintained in the medium. GM-CSF neither suppressed nor augmented HIV replication. The combination of AZT/GM-CSF was comparable with AZT alone in sup-
ELLS OF T H E MONOCYTE/macrophage lineage
C are currently recognized as important targets and probable reservoirs of human immunodeficiency virus (HIV) infection.'-6 Therefore, antiviral strategies must be devised that are effective in inhibiting virus replication within this cell population and, equally importantly, must attempt to prevent transfer of HIV from already infected macrophages to target lymphocytes. Primary infection of monocyte/ macrophages is thought to be critical in the neurologic disease caused by HIV,' and the "reservoir" function of this cell lineage may be responsible for the ongoing infection of CD4 lymphocytes, resulting in the progressive immunoincompetence observed in the acquired immunodeficiency syndrome (AIDS). Zidovudine (azidothymidine; AZT) has demonstrated in vitro anti-HIV activity in lymphoid cells and clinical efficacy in a double-blind, placebo-controlled trial in individuals with AIDS or AIDS-related complex Recently, however, it was reported to be ineffective in peripheral blood monocytes because these cells did not phosphorylate the parent compound." In contrast, a subsequent study by Perno et a1 described the effectiveness of AZT in inhibiting a monocytotropic isolate of HIV-type 1 (HIV-1) in peripheral blood monocytes." Phosphorylation of the drug was reduced, but the ratio of AZT triphosphate to the normal deoxynucleoside triphosphate pool was thought to be important in the drug's activity." We have found AZT to be inhibitory to the replication of the IIIB strain of HIV-1 in U937 cells, a monocytic cell line, and to act synergistically with granulocyte-macrophage colony-stimulating factor (GM-CSF) versus HIV-1 in this cell line.12.13 GM-CSF, which holds great promise in the treatment of the cytopenias associated with AIDS and ~hemotherapy,'~ has raised concerns, however, in the setting of HIV infection, as it has been shown to upregulate HIV in a nonproductive clone of U937 cells.'' In studies using primary peripheral blood monocyte cultures, Koyanagi et a1,I6 and Perno et all' have both described enhancement of HIV-1 replication by GM-CSF when applied either post-or pre-virus exposure, respectively. The purpose of this study was to examine the effects of AZT and GM-CSF, both alone and in combination, on the in vitro pressing both the initial infection of AMs and the transfer t o target PBMLs as long as the agents were maintained in the cultures. However, when the drugs were removed at the same time that PHA-stimulated PBMLs were added t o the culture, the combination of AZT/GM-CSF was found t o be more effective than AZT alone in preventing the transfer/amplification of HIV in the target lymphocytes. These results suggest that (1 ) AZT is effective in inhibiting HIV-1 infection in mononuclear phagocytes; (2) GM-CSF neither inhibits nor augments the replication of the Ill6 HIV infection of normal alveolar macrophages (AMs), a representative tissue macrophage, in view of the previously encouraging results seen in the U937 system.
MATERIALS AND METHODS
Cells and media. Alveolar macrophages were obtained by broncholavage from HIV seronegative, normal human volunteers by standard techniques' after written informed consent was obtained approved by our Institutional Review Board. The cells were washed in serum-free medium, placed in 35 mm, six-well plates (Costar, Cambridge, MA) at a concentration of 2 x lo6 cells per well, and, after a 2-hour incubation, nonadherent cells were removed. The remaining adherent cells were determined to be greater than 95% macrophages by phagocytosis of 1.1 Mm latex beads. AMs were maintained in RPMI 1640 medium supplemented with 250 U/mL penicillin, 250 pg/mL streptomycin, 2 mmol/L L-glutamine, 10 mmol/L HEPES buffer, and 10% fetal calf serum (FCS; MA Bioproducts, Walkersville, MD).
The IIIB strain of HIV-1 (courtesy R.C. Gallo, National Cancer Institute) was propagated in H9 cells that, in turn, were maintained in RPMI 1640 medium supplemented with penicillin, streptomycin, L-glutamine, HEPES buffer, and 20% FCS. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Genetics Institute, Cambridge, MA) had a specific activity of 4.1 x IO6 U/mg protein and was stored at -7OOC. The concentrations of the compounds used in these studies were based on our previous findings of their antiretroviral activity in the U937 cell line." AM monolayers were incubated in medium alone or medium containing 30 U/mL GM-CSF for 48 to 72 hours. After this incubation, the monolayers were washed, incubated with 25 pg/mL diethyl aminoethyl (DEAE) dextran for 30 minutes and infected with an inoculum of HIV consisting of 1 mL of a filtered, cell-free culture supernatant (mean reverse transcriptase activity [RT] of inocula = 5.6 log,, cpm/mL) for 2 hours at 37OC. After the virus adsorption period, cultures that had been pretreated with GM-CSF were re-exposed to this compound alone or in combination with 1 pmol/L AZT. Cultures that had been incubated in medium alone pre-infection were left untreated or were exposed to 1 pmol/L AZT immediately postinfection. Controls included mock infected cultures maintained in medium alone or medium containing 30 U/mL GM-CSF and/or 1 pmollL AZT. Drugs were replaced in the culture supernatants with each media change.
Ten days post-infection, phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear leukocytes (PBMLs) from HIV seronegative donors were added to some of the AM cultures as target cells ( 5 x IO5 PBMLs per well). Cultures were then followed for an additional 10 days, during which drug was maintained in the treated cultures.
To determine the effect of drug removal in this system, cultures that had been maintained for 20 days in the presence of AZT and/or GM-CSF, but to which PBMLs had not been previously added, were washed free of drug, and PHA-stimulated PBMLs were added at that point. These cultures were then monitored for an additional 15 days.
Cultures were examined visually with an Olympus Model CK indirect microscope for evidence of cytopathic effects (CPE) or cytotoxicity. Evidence for HIV replication in the culture supernatants was evaluated by supernatant HIV antigen (Ag) determination by enzyme immunoassay (DuPont, Boston, MA) and by supernatant RT activity by standard techniques.18
Statistics. The Student's t test was used for all statistical comparisons.
HIV infection of AMsldrug treatment.
Monitoring cultures.

RESULTS
In our experience, when normal AMs are infected in vitro with the IIIB strain of HIV-1, they exhibit no cytopathic effects and supernatant R T activity falls to low or undetectable levels by days 5 to 7 post-infection. Supernatant HIV antigen also predictably falls post-HIV exposure, but it remains detectable for up to 6 weeks if the cells are left in culture, usually in the range of 100 to 900 pg/mL. This indicates that a low-level, non-cytopathic infection is established in these cultures. If stimulated target cells, such as PHA-stimulated PBMLs are added a t any point postinfection, a marked rise in R T activity and supernatant HIV antigen is seen within 4 days of their addition. This pattern of in vitro HIV infection has been observed consistently in over 30 A M cultures established from normal donors in our laboratory, and no differences have been observed with respect to the age, sex, or smoking status of the donor. We have specifically chosen the IIIB strain of HIV-1 for these studies because, in our laboratory, it consistently produces a low-level productive infection that permits the system to mimic the "reservoir" function presumed for monocyte/ This system thus offers the opportunity to examine antiviral strategies designed to prevent primary infection of macrophages, as well as to inhibit transfer of infection from already infected macrophages to target lymphocytes.
In our experiments, the control infected AM's demonstrated the typical pattern of in vitro HIV infection described above. The cells demonstrated no CPE, had falling supernatant R T activities, and persistent supernatant Ag levels post-infection. After the addition of stimulated PBMLs, there was a brisk rise in both measures of HIV replication within 3 days of their addition ( Figs 1A and 2A) .
Addition of 1 pmol/L AZT immediately post-infection resulted in significant antiviral activity by days 6 and 10 post-infection. Mean HIV Ag levels in infected control cultures were reduced from 8 13 (k 128) to 180 (k 17) pg/mL (P = .001), and from 808 (+119) to 22 (+9) pg/mL (P < .001) on days 6 and 10, respectively, by AZT alone (Fig   2A and B) . RT activities and HIV antigens subsequently fell to undetectable levels in treated cultures and, impressively, remained undetectable in cultures that received PBMLs as long as AZT was maintained in the medium (Figs 1B and 2B). The persistent inhibitory effect of AZT after PBML addition may have reflected its activity in both the AM and target T-cell populations.
In contrast, pretreatment of AMs with GM-CSF at 30 U/mL and maintenance of the cytokine in the cultures demonstrated no inhibitory effect on HIV replication. Levels of R T activities and HIV antigens were comparable with the infected control cultures in the 10 days post-infection, and there was no inhibition of transfer of infection to target PBML's (Figs 1C and 2C) . Importantly, however, there was clearly no potentiation of HIV replication as measured by supernatant parameters of infection. On days 6 and 10 post-infection, mean HIV antigen levels were reduced from 813 (+128) to 201 (523) pg/mL (P = .002) and from 808 (5119) to 41 (512) pg/mL (P < .001), respectively (Fig 2A and D) . The combination was also effective in inhibiting transfer of infection to target PBMLs ( Figs 1D and 2D) . These results were comparable to those observed with 1 Nmol/L AZT alone. Given the marked effectiveness of AZT alone, an additive effect of GM-CSF could not be elucidated. Notably, however, no antagonism of the effectiveness of AZT was demonstrated.
We next examined the pattern of HIV expression after drug removal and attempted to determine if virus expression could be observed in the cultures that had been completely suppressed by AZT or AZT + GM-CSF. To do this, infected A M monolayers that had been maintained in culture with or without drug exposure for 20 days post-infection were washed thoroughly, and PHA-stimulated PBMLs were added to the wells. The cultures were monitored for supernatant HIV antigen for 15 days, and representative results are shown in Fig 3. Supernatant antigen expression briskly rose in a comparable manner in infected control and GM-CSFexposed cultures. In previously AZT-exposed cultures, virus expression was delayed after PBML addition compared with control cultures, but was still readily apparent by day 8 post-drug removal. In contrast, in four of six experiments, the combination of AZT + GM-CSF appeared to have a greater antiretroviral effect than AZT alone, in that virus expression was not seen after PBML addition and drug removal. In the other two experiments, the results with AZT + GM-CSF were comparable with AZT alone. Thus, although no differences in efficacy of viral inhibition could be seen between AZT and AZT + GM-CSF-treated cultures when drug was continuously present (Figs 1 and 2) , differences became apparent after drug removal in the majority of studies ( Fig   No cytotoxic effects of AZT and/or GM-CSF were noted in AM cultures or in cultures treated with concentrations 10-fold higher than those used in these studies.
3).
DISCUSSION
The increasingly recognized role of the monocyte/ macrophage in the pathogenesis of HIV-related disorders has made it important to examine the efficacy of antiviral agents in cells of this lineage in addition to lymphoid cell systems. To this end, we have previously used the U937 monocytic cell line to examine the anti-HIV-1 activity of AZT, GM-CSF, and interfer~n-gamma.'~.'~ All showed inhibitory activity in this system, with the combination of AZT + GM-CSF demonstrating synergism. Despite the usefulness of continuous cell lines, it is important to examine the efficacy and potential toxicity of antiviral agents in normal human cells. We have chosen AMs obtained by bronchoalveolar lavage for this purpose, as they represent a differentiated tissue macrophage which can be placed in culture in a high degree of purity. The limitations of this system are the necessity for an invasive procedure to obtain the cells and the relatively small number of cells retrieved. In this study, we chose to try to extend our previous findings For personal use only. on October 3, 2017. by guest www.bloodjournal.org From confirms the reported efficacy of AZT in monocytic cell systems described by Perno et al."
In contrast to the results in U937 cells, GM-CSF was not demonstrated to have antiviral activity in AMs. Importantly, however, potentiation of HIV replication was not demonstrated. This is relevant given the recent observation that this cytokine can upregulate the HIV genome in a nonproductive clone (designated U1) of U937 cells and in peripheral blood mono~ytes.'~-'' However, in the latter report by Perno et HIV replication in blood monocytes that were permitted to mature in vitro for 5 days was not affected by GM-CSF, a result consistent with our findings in a differentiated tissue macrophage. Whether the differential effect of GM-CSF on HIV replication in monocytes versus mature macrophages is related to the state of cellular differentiation or the number of cellular receptors for GM-CSF is not yet entirely clear.17
The ability of human AMs to respond to GM-CSF in other biologic systems'' implies the presence of GM-CSF receptors, and these cells have recently been directly shown to possess approximately 350 GM-CSF receptors per cell," a figure comparable with that reported for blood monocytes."
In addition, our results indicate that the relatively lymphocytotropic HIV strain, IIIB, was not converted to a more monocytotropic strain in AMs, as has been noted in peripheral blood monocytes." We specifically decided to use the IIIB strain in these studies in order to achieve the low-level, productive infection desired (see "Results") and to examine the question of "conversion" of the tropic characteristics of an isolate by GM-CSF. It should also be noted that although the IIIB strain is generally termed lymphocytotropic, this is only a relative characteristic, as illustrated by the infected laboratory worker from whom the IIIB strain was isolated only from the blood monocyte fraction without a detectable viral genomic alteration." As GM-CSF has been, and is currently, in clinical trials in HIV-infected individuals, it is important to try to determine if this upregulation occurs in normal cells in vitro or in vivo. Although we did not examine these cells for viral mRNA or for the intracellular accumulation of virions in vacuoles, our data are encouraging with regard to supernatant parameters of HIV replication and the transfer to target lymphocytes. We have examined GM-CSF at concentrations up to 300 U/mL in the A M system and have confirmed that neither inhibitory nor stimulatory effects on HIV,,,, replication in AMs are seen (data not shown). Furthermore, in clinical trials in which GM-CSF has been given long-term to individuals with HIV infection, no consistent alterations in serum HIV antigen have been noted (J. Groopman, personal communication, October 1989).
The combination of AZT + GM-CSF demonstrated anti-HIV activity comparable with AZT alone at the concentrations examined. The degree of effectiveness of AZT precluded the ability to demonstrate an additive or synergistic effect of GM-CSF but, perhaps just as importantly, no antagonism was demonstrated. This is encouraging, as GM-CSF has demonstrated efficacy in reversing the cytopenias seen in HIV infected individual^'^ and there is great interest in using GM-CSF to diminish the toxicity of AZT, irrespective of whether it possesses any antiviral activity of its own.
The inability to induce virus replication in four of six AZT + GM-CSF-treated cultures after drug removal and PBML addition is of interest in that it suggests an additive antiviral effect of the combination. This may well be explained by the recent report of GM-CSF's ability to increase the anabolic phosphorylation of AZT in monocytes, resulting in a lowering of the AZT ED,,."
In summary, our results suggest that AZT is an effective anti-HIV-1 agent in cells of macrophage lineage and that its activity is not antagonized, and may be augmented, by GM-CSF. This study lends further support to the planned human trials using these agents in combination.
